Stereotaxis, Inc. officially completed its initial public offering and began trading its common stock on public markets in August 2004. The medical device pioneer transitioned into a publicly traded corporation to raise institutional capital, fund clinical trials, and scale its proprietary robotic magnetic navigation systems for electrophysiology and minimally invasive endovascular surgical interventions across global hospital networks.